CN100396283C - Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 - Google Patents

Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 Download PDF

Info

Publication number
CN100396283C
CN100396283C CNB018149243A CN01814924A CN100396283C CN 100396283 C CN100396283 C CN 100396283C CN B018149243 A CNB018149243 A CN B018149243A CN 01814924 A CN01814924 A CN 01814924A CN 100396283 C CN100396283 C CN 100396283C
Authority
CN
China
Prior art keywords
alkyl
aryl
group
perhaps
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018149243A
Other languages
English (en)
Chinese (zh)
Other versions
CN1599612A (zh
Inventor
P·D·范佩尔耶
M·D·埃里安
藤原俊彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Metabasis Therapeutics Inc
Original Assignee
Sankyo Co Ltd
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Metabasis Therapeutics Inc filed Critical Sankyo Co Ltd
Publication of CN1599612A publication Critical patent/CN1599612A/zh
Application granted granted Critical
Publication of CN100396283C publication Critical patent/CN100396283C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018149243A 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 Expired - Fee Related CN100396283C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200810098112XA Division CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Publications (2)

Publication Number Publication Date
CN1599612A CN1599612A (zh) 2005-03-23
CN100396283C true CN100396283C (zh) 2008-06-25

Family

ID=22807416

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018149243A Expired - Fee Related CN100396283C (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
CNA200810098112XA Pending CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200810098112XA Pending CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Country Status (18)

Country Link
EP (1) EP1372660A2 (fr)
JP (1) JP2004508297A (fr)
KR (1) KR100854851B1 (fr)
CN (2) CN100396283C (fr)
AU (2) AU7327101A (fr)
BR (1) BR0112212A (fr)
CA (1) CA2412142A1 (fr)
CZ (1) CZ20035A3 (fr)
HU (1) HUP0301830A3 (fr)
IL (2) IL153513A0 (fr)
MX (1) MXPA02012713A (fr)
NO (1) NO20030034L (fr)
NZ (1) NZ523227A (fr)
PL (1) PL365779A1 (fr)
RU (1) RU2328308C2 (fr)
SK (1) SK62003A3 (fr)
WO (1) WO2002003978A2 (fr)
ZA (1) ZA200300044B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831437A (zh) * 2016-02-03 2017-06-13 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
IL151248A0 (en) 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CN1902196B (zh) 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
BRPI0514372A (pt) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche
WO2008063842A2 (fr) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
TWI606848B (zh) * 2012-10-08 2017-12-01 Lg生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (fr) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
CN1400908A (zh) * 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶-iv抑制剂的联合形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
ES2210728T3 (es) * 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DK1112275T3 (da) * 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
NZ512219A (en) * 1998-12-24 2004-12-24 Metabasis Therapeutics Inc A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (fr) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
CN1400908A (zh) * 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶-iv抑制剂的联合形式

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831437A (zh) * 2016-02-03 2017-06-13 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用

Also Published As

Publication number Publication date
KR20030031952A (ko) 2003-04-23
NO20030034L (no) 2003-03-05
HUP0301830A2 (hu) 2003-11-28
IL153513A0 (en) 2003-07-06
JP2004508297A (ja) 2004-03-18
EP1372660A2 (fr) 2004-01-02
BR0112212A (pt) 2003-12-30
NZ523227A (en) 2005-04-29
ZA200300044B (en) 2004-05-06
AU2001273271B2 (en) 2006-01-05
IL153513A (en) 2014-07-31
KR100854851B1 (ko) 2008-08-27
WO2002003978A2 (fr) 2002-01-17
NO20030034D0 (no) 2003-01-03
HUP0301830A3 (en) 2007-10-29
SK62003A3 (en) 2003-09-11
AU7327101A (en) 2002-01-21
CA2412142A1 (fr) 2002-01-17
PL365779A1 (en) 2005-01-10
WO2002003978A3 (fr) 2003-10-16
CN1599612A (zh) 2005-03-23
MXPA02012713A (es) 2004-09-10
CN101301294A (zh) 2008-11-12
RU2328308C2 (ru) 2008-07-10
CZ20035A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
CN100396283C (zh) Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
CN100352505C (zh) 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
JPH06184116A (ja) 医薬組成物
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK8892002A3 (en) Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CA2344309A1 (fr) Procede de traitement de diabetes a l'aide de l'inhibiteur ap2 et combinaison associee
JPH11302177A (ja) 腎炎治療剤
AU2006265653A1 (en) Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
NZ523189A (en) Benzodiazepine (BZP) receptor inverse agonists for the prevention and treatment of alzheimer's disease and schizophrenia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: METABASIS THERAPEUTICS INC.

Free format text: FORMER OWNER: METABASIS THERAPEUTICS INC.; FIRST SANKYO CO., LTD.

Effective date: 20080704

Owner name: METABASIS THERAPEUTICS INC.; FIRST SANKYO CO., LT

Free format text: FORMER OWNER: METABASIS THERAPEUTICS INC.; SANKYO CO., LTD.

Effective date: 20080704

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080704

Address after: California, USA

Patentee after: METABASIS THERAPEUTICS, Inc.

Address before: California, USA

Co-patentee before: DAIICHI SANKYO Co.,Ltd.

Patentee before: METABASIS THERAPEUTICS, Inc.

Effective date of registration: 20080704

Address after: California, USA

Co-patentee after: DAIICHI SANKYO Co.,Ltd.

Patentee after: METABASIS THERAPEUTICS, Inc.

Address before: California, USA

Co-patentee before: Sankyo Co.,Ltd.

Patentee before: METABASIS THERAPEUTICS, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080625

Termination date: 20180705